Srđan Verstovšek

Research interests

Publications

• The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

  Leukemia · 2022 · https://doi.org/10.1038/s41375-022-01613-1

• 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

  The Lancet Haematology · 2020 · https://doi.org/10.1016/s2352-3026(20)30210-6

• Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

  Leukemia · 2018 · https://doi.org/10.1038/s41375-018-0077-1

• Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

  The Lancet Haematology · 2017 · https://doi.org/10.1016/s2352-3026(17)30237-5

• Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation

  Blood · 2017 · https://doi.org/10.1182/blood-2017-05-783225

• Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

  Blood · 2016 · https://doi.org/10.1182/blood-2016-09-736686

• Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with P hiladelphia chromosome–positive acute lymphoblastic leukemia

  Cancer · 2015 · https://doi.org/10.1002/cncr.29646

• Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1409002

• Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib

  Blood · 2015 · https://doi.org/10.1182/blood-2015-03-633404

• Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms

  Proceedings of the National Academy of Sciences · 2014 · https://doi.org/10.1073/pnas.1407792111

• Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

  Blood · 2013 · https://doi.org/10.1182/blood-2013-03-488098

• Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project

  Blood · 2013 · https://doi.org/10.1182/blood-2013-01-478891

• Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

  Blood · 2012 · https://doi.org/10.1182/blood-2012-02-414631

• Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2010.31.8436

• Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2009.26.9456

• Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

  Blood · 2010 · https://doi.org/10.1182/blood-2009-04-214957

• The natural history and treatment outcome of blast phase BCR-ABL− myeloproliferative neoplasms

  Blood · 2008 · https://doi.org/10.1182/blood-2008-02-138230

• Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin

  Journal of Clinical Oncology · 2008 · https://doi.org/10.1200/jco.2008.18.6130

• Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

  Blood · 2007 · https://doi.org/10.1182/blood-2007-04-083501

• Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment

  Leukemia · 2007 · https://doi.org/10.1038/sj.leu.2404914

• Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)

  Leukemia Research · 2007 · https://doi.org/10.1016/j.leukres.2006.12.002

• Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia

  Cancer · 2006 · https://doi.org/10.1002/cncr.21776

• Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia

  Blood · 2006 · https://doi.org/10.1182/blood-2006-03-009142

• Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

  Leukemia · 2006 · https://doi.org/10.1038/sj.leu.2404318

• High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia

  Blood · 2003 · https://doi.org/10.1182/blood-2003-11-3800

Current projects

No projects listed.